Literature DB >> 15020838

The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA).

Paul A Marks1.   

Abstract

Histone deacetylases (HDAC) are ubiquitously distributed through chromatin. Nevertheless HDAC inhibitors (HDACi), such as SAHA, selectively alter the transcription of as few as 2-5% of expressed genes in various transformed cells. p21(WAF1) is one of the most commonly induced genes in cells cultured with SAHA. Understanding the mechanism of the selective effects of the HDACi is a challenging problem. Gui et al. have identified effects of SAHA on p21(WAF1) promotor associated proteins that explain, at least in part, the selective effects of HDAC in altering gene expression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15020838     DOI: 10.4161/cc.3.5.827

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  18 in total

1.  A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia.

Authors:  Tapan M Kadia; Hui Yang; Alessandra Ferrajoli; Sirisha Maddipotti; Claudia Schroeder; Timothy L Madden; Julianne L Holleran; Merrill J Egorin; Farhad Ravandi; Deborah A Thomas; Willie Newsome; Blanca Sanchez-Gonzalez; James A Zwiebel; Igor Espinoza-Delgado; Hagop M Kantarjian; Guillermo Garcia-Manero
Journal:  Br J Haematol       Date:  2010-04-29       Impact factor: 6.998

Review 2.  Mechanisms of aromatase inhibitor resistance.

Authors:  Cynthia X Ma; Tomás Reinert; Izabela Chmielewska; Matthew J Ellis
Journal:  Nat Rev Cancer       Date:  2015-05       Impact factor: 60.716

Review 3.  Cutaneous T-cell lymphoma: Biologic targets for therapy.

Authors:  Jaehyuk Choi; Francine Foss
Journal:  Curr Hematol Malig Rep       Date:  2007-10       Impact factor: 3.952

4.  Protein arginine deiminase 4: a target for an epigenetic cancer therapy.

Authors:  Jessica L Slack; Corey P Causey; Paul R Thompson
Journal:  Cell Mol Life Sci       Date:  2010-08-13       Impact factor: 9.261

5.  Enhanced radiosensitivity of EC109 cells by inhibition of HDAC1 expression.

Authors:  Bo Zhang; Yan Wang; Xueli Pang
Journal:  Med Oncol       Date:  2010-05-13       Impact factor: 3.064

6.  PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.

Authors:  Girija Dasmahapatra; Hiral Patel; Tri Nguyen; Elisa Attkisson; Steven Grant
Journal:  Clin Cancer Res       Date:  2012-11-30       Impact factor: 12.531

Review 7.  Epigenetic mechanisms in cerebral ischemia.

Authors:  Sophie Schweizer; Andreas Meisel; Stefanie Märschenz
Journal:  J Cereb Blood Flow Metab       Date:  2013-06-12       Impact factor: 6.200

8.  Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells.

Authors:  Rayna Rosati; Bailing Chen; Mugdha Patki; Thomas McFall; Siyu Ou; Elisabeth Heath; Manohar Ratnam; Zhihui Qin
Journal:  Mol Pharmacol       Date:  2016-07-05       Impact factor: 4.436

9.  A chemocentric approach to the identification of cancer targets.

Authors:  Beáta Flachner; Zsolt Lörincz; Angelo Carotti; Orazio Nicolotti; Praveena Kuchipudi; Nikita Remez; Ferran Sanz; József Tóvári; Miklós J Szabó; Béla Bertók; Sándor Cseh; Jordi Mestres; György Dormán
Journal:  PLoS One       Date:  2012-04-25       Impact factor: 3.240

Review 10.  Epigenetic-Based Therapy-A Prospective Chance for Medulloblastoma Patients' Recovery.

Authors:  Agata Strejczek; Dawid Woszczyk; Helena Urbaniak; Martyna Różańska; Michał Robak; Zofia Matuszewska; Anna-Maria Barciszewska
Journal:  Int J Mol Sci       Date:  2021-05-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.